Quantcast

Industry news that matters to you.  Learn more

Assurex Health Releases Major Update to GeneSight Psychotropic Test Panel

Assurex Health recently announced the release of GeneSight® Psychotropic 2.0, its lead psychiatric pharmacogenomic test panel. This latest GeneSight Psychotropic version has been updated to include four additional medications that now cover a total of 36 of the most commonly prescribed psychotropic medications in the US. The added antidepressant and antipsychotic medications include Viibryd® (vilazodone), Latuda® (lurasidone), Saphris® (asenapine), and Invega® (paliperidone). Additionally, the GeneSight Psychotropic 2.0 report includes information for 17 psychotropic medications that have pharmacogenomic information in their FDA approved labels.

“Assurex Health is committed to bringing the latest clinical and scientific findings to support clinicians and their patients in selecting medications to treat neuropsychiatric disorders,” according to Bryan M. Dechairo, Ph.D., Senior Vice President, Medical Affairs & Clinical Development at Assurex Health. “GeneSight Psychotropic 2.0 now includes recently approved FDA medications, a new gene polymorphism, and easy-to-understand information to help categorize individual psychotropic medications.”

GeneSight is a unique pharmacogenomic treatment decision support product that tests for clinically important genetic variants affecting a patient’s response to psychiatric medications. GeneSight provides information that helps clinicians make informed, evidence-based decisions about proper drug selection, delivered in a simple and easily understood report. Prescribing a medication regimen that is more likely to succeed because it is tailored to an individual patient’s genetic profile can help the clinician better manage the patient’s disease and improve patient outcomes.

A Mayo Clinic prospective clinical study published recently in Translational Psychiatry (Oct. 2012) compared GeneSight-guided prescribing versus treatment-as-usual prescribing in adult patients with a primary diagnosis of a major depressive disorder over an 8 week period. The study found up to a 4-fold increase in symptom improvement for GeneSight-guided patients. An Assurex Health sponsored one-year blinded retrospective study of adult patients with a diagnosis of depressive or anxiety disorder, also published recently in Translational Psychiatry (Mar. 2013), demonstrated that patients taking genetically inappropriate or “red bin” medications based on the GeneSight report had substantially higher rates of medical utilization, 3-fold greater medical absence days, and 4-fold greater medical disability claims than study patients on non-red bin medications.

Source: Assurex Health

Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, recently announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.

Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel

Nanōmix Inc., (Nanōmix), a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, recently announced that it has initiated clinical testing in the U.S. to evaluate the Omega 3 Cardiac Panel.

Quest Diagnostics Launches New Molecular Test Panel for Enhanced Thyroid Cancer Detection

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal. The test is believed to be the most comprehensive panel clinically available to identify mutations associated with four gene markers indicated by the American Thyroid Association for the clinical management of indeterminate thyroid biopsies.

OPKO Health Acquires Next Generation Prostate Cancer Tests

OPKO Health, Inc. yesterday announced the acquisition of an exclusive license from Arctic Partners Ab Oy (Turku, Finland) for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%. These novel biomarkers were developed by investigators at the University of Malmo, Sweden, University of Turku, Finland, and Memorial Sloan Kettering Cancer Center, New York. The research results indicate that these markers can predict initial biopsy results in men suspected of having prostate cancer; they have been tested in over 8,000 men and were independently validated in the European Randomized Study of Prostate Cancer Screening (Rotterdam).